Emcure Pharmaceuticals and Sanofi India Announce Exclusive Partnership for Oral Anti-diabetic Drugs Distribution

Emcure Pharmaceuticals Ltd. and Sanofi India Limited have entered into an exclusive distribution and promotion agreement for Sanofi’s oral anti-diabetic (OAD) products in India. Emcure will exclusively distribute and promote Sanofi’s OAD range of products, including the well-established brands Amaryl’ and Cetapin’. Sanofi will continue to own and manufacture these brands. The partnership aims to expand the reach of these therapeutic solutions for patients across India, leveraging Emcure’s wide and deeply penetrated presence. There will be no people transition from SIL to Emcure in this arrangement. The partnership is expected to benefit patients and healthcare professionals by improving access to Sanofi’s trusted oral anti-diabetic medicines.